Literature DB >> 24778809

Combinatorial delivery of immunosuppressive factors to dendritic cells using dual-sized microspheres.

Jamal S Lewis1, Chris Roche1, Ying Zhang1, Todd M Brusko2, Clive H Wasserfall2, Mark Atkinson2, Michael J Clare-Salzler2, Benjamin G Keselowsky1.   

Abstract

Microparticulate systems are beginning to show promise for delivery of modulatory agents for immunotherapeutic applications which modulate dendritic cell (DC) functions. Co-administration of multiple factors is an emerging theme in immune modulation which may prove beneficial in this setting. Herein, we demonstrate that localized, controlled delivery of multiple factors can be accomplished through poly (lactic-co-glycolic acid) (PLGA) microparticle systems fabricated in two size classes of phagocytosable and unphagocytosable microparticles (MPs). The immunosuppressive ability of combinatorial multi-factor dual MP systems was evaluated by investigating effects on DC maturation, DC resistance to LPS-mediated maturation and proliferation of allogeneic T cells in a mixed lymphocyte reaction. Phagocytosable MPs (~2 μm) were fabricated encapsulating either rapamycin (RAPA) or all-trans retinoic acid (RA), and unphagocytosable MPs (~30 μm) were fabricated encapsulating either transforming growth factor beta-1 (TGF-β1) or interleukin-10 (IL-10). Combinations of these MP classes reduced expression of stimulatory/costimulatory molecules (MHC-II, CD80 and CD86) in comparison to iDC and soluble controls, but not necessarily to single factor MPs. Dual MP-treated DCs resisted LPS-mediated activation, in a manner driven by the single factor phagocytosable MPs used. Dendritic cells treated with dual MP systems suppressed allogeneic T cell proliferation, generally demonstrating greater suppression by combination MPs than single factor formulations, particularly for the RA/IL-10 MPs. This work demonstrates feasibility of simultaneous targeted delivery of immunomodulatory factors to cell surface receptors and intracellular locations, and indicates that a combinatorial approach can boost immunoregulatory responses for therapeutic application in autoimmunity and transplantation.

Entities:  

Year:  2014        PMID: 24778809      PMCID: PMC4000038          DOI: 10.1039/C3TB21460E

Source DB:  PubMed          Journal:  J Mater Chem B        ISSN: 2050-750X            Impact factor:   6.331


  60 in total

Review 1.  Multifunctional dendritic cell-targeting polymeric microparticles: engineering new vaccines for type 1 diabetes.

Authors:  Benjamin G Keselowsky; Chang Qing Xia; Michael Clare-Salzler
Journal:  Hum Vaccin       Date:  2011-01-01

2.  Controlled release formulations of IL-2, TGF-β1 and rapamycin for the induction of regulatory T cells.

Authors:  Siddharth Jhunjhunwala; Stephen C Balmert; Giorgio Raimondi; Eefje Dons; Erin E Nichols; Angus W Thomson; Steven R Little
Journal:  J Control Release       Date:  2012-01-21       Impact factor: 9.776

Review 3.  Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting.

Authors:  Paul J Tacken; I Jolanda M de Vries; Ruurd Torensma; Carl G Figdor
Journal:  Nat Rev Immunol       Date:  2007-10       Impact factor: 53.106

Review 4.  Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens.

Authors:  Wenlei Jiang; Rajesh K Gupta; Mangesh C Deshpande; Steven P Schwendeman
Journal:  Adv Drug Deliv Rev       Date:  2005-01-10       Impact factor: 15.470

5.  Dendritic cells with TGF-beta1 differentiate naive CD4+CD25- T cells into islet-protective Foxp3+ regulatory T cells.

Authors:  Xunrong Luo; Kristin V Tarbell; Hua Yang; Kathryn Pothoven; Samantha L Bailey; Ruchuang Ding; Ralph M Steinman; Manikkam Suthanthiran
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-16       Impact factor: 11.205

6.  Retinoic acid inhibits Th17 polarization and enhances FoxP3 expression through a Stat-3/Stat-5 independent signaling pathway.

Authors:  Kevin M Elias; Arian Laurence; Todd S Davidson; Geoffrey Stephens; Yuka Kanno; Ethan M Shevach; John J O'Shea
Journal:  Blood       Date:  2007-10-19       Impact factor: 22.113

Review 7.  Taming the lions: manipulating dendritic cells for use as negative cellular vaccines in organ transplantation.

Authors:  Hēth R Turnquist; Angus W Thomson
Journal:  Curr Opin Organ Transplant       Date:  2008-08       Impact factor: 2.640

8.  Interleukin-10 induces the upregulation of the inhibitory receptor ILT4 in monocytes from HIV positive individuals.

Authors:  George Vlad; Flavia Piazza; Adriana Colovai; Raffaello Cortesini; Fatima Della Pietra; Nicole Suciu-Foca; John S Manavalan
Journal:  Hum Immunol       Date:  2003-05       Impact factor: 2.850

9.  Induction of regulatory dendritic cells by dexamethasone and 1alpha,25-Dihydroxyvitamin D(3).

Authors:  Anders Elm Pedersen; Monika Gad; Mark R Walter; Mogens Helweg Claesson
Journal:  Immunol Lett       Date:  2004-01-30       Impact factor: 3.685

10.  TGF-beta and kynurenines as the key to infectious tolerance.

Authors:  Maria L Belladonna; Ciriana Orabona; Ursula Grohmann; Paolo Puccetti
Journal:  Trends Mol Med       Date:  2009-01-21       Impact factor: 11.951

View more
  31 in total

1.  An antigen-specific semi-therapeutic treatment with local delivery of tolerogenic factors through a dual-sized microparticle system blocks experimental autoimmune encephalomyelitis.

Authors:  Jonathan J Cho; Joshua M Stewart; Theodore T Drashansky; Maigan A Brusko; Ashley N Zuniga; Kyle J Lorentsen; Benjamin G Keselowsky; Dorina Avram
Journal:  Biomaterials       Date:  2017-07-24       Impact factor: 12.479

2.  Engineering Biomaterials to Direct Innate Immunity.

Authors:  R S Oakes; E Froimchuk; C M Jewell
Journal:  Adv Ther (Weinh)       Date:  2019-02-27

Review 3.  Micro and nanoparticle drug delivery systems for preventing allotransplant rejection.

Authors:  James D Fisher; Abhinav P Acharya; Steven R Little
Journal:  Clin Immunol       Date:  2015-05-01       Impact factor: 3.969

4.  A combination dual-sized microparticle system modulates dendritic cells and prevents type 1 diabetes in prediabetic NOD mice.

Authors:  Jamal S Lewis; Natalia V Dolgova; Ying Zhang; Chang Qing Xia; Clive H Wasserfall; Mark A Atkinson; Michael J Clare-Salzler; Benjamin G Keselowsky
Journal:  Clin Immunol       Date:  2015-04-02       Impact factor: 3.969

Review 5.  Applied Bioengineering in Tissue Reconstruction, Replacement, and Regeneration.

Authors:  Juan M Colazo; Brian C Evans; Angel F Farinas; Salam Al-Kassis; Craig L Duvall; Wesley P Thayer
Journal:  Tissue Eng Part B Rev       Date:  2019-08       Impact factor: 6.389

Review 6.  Active targeted delivery of immune therapeutics to lymph nodes.

Authors:  Baharak Bahmani; Ishaan Vohra; Nazila Kamaly; Reza Abdi
Journal:  Curr Opin Organ Transplant       Date:  2018-02       Impact factor: 2.640

7.  Conjugation of Transforming Growth Factor Beta to Antigen-Loaded Poly(lactide- co-glycolide) Nanoparticles Enhances Efficiency of Antigen-Specific Tolerance.

Authors:  Liam M Casey; Ryan M Pearson; Kevin R Hughes; Jeffrey M H Liu; Justin A Rose; Madeleine G North; Leon Z Wang; Mei Lei; Stephen D Miller; Lonnie D Shea
Journal:  Bioconjug Chem       Date:  2017-11-30       Impact factor: 4.774

8.  Toward Personalized Peptide-Based Cancer Nanovaccines: A Facile and Versatile Synthetic Approach.

Authors:  Hamilton Kakwere; Elizabeth S Ingham; Riley Allen; Lisa M Mahakian; Sarah M Tam; Hua Zhang; Matthew T Silvestrini; Jamal S Lewis; Katherine W Ferrara
Journal:  Bioconjug Chem       Date:  2017-10-13       Impact factor: 4.774

Review 9.  Engineering Immune Tolerance with Biomaterials.

Authors:  Joshua M Gammon; Christopher M Jewell
Journal:  Adv Healthc Mater       Date:  2019-01-03       Impact factor: 9.933

10.  Formulation and characterization of poly(propylacrylic acid)/poly(lactic-co-glycolic acid) blend microparticles for pH-dependent membrane disruption and cytosolic delivery.

Authors:  Lawrence P Fernando; Jamal S Lewis; Brian C Evans; Craig L Duvall; Benjamin G Keselowsky
Journal:  J Biomed Mater Res A       Date:  2017-12-21       Impact factor: 4.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.